Patent intelligence · US
US 9657288
Connector compound peptide phage display
Connector compound peptide phage display
Patent details — US 9657288
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 23, 2017
- Expiration
- May 18, 2037
- Applicant
- BICYCLE THERAPEUTICS LIMITED
- Claims
- 7
- CPC classes
- A61K, A61K47/54, A61K47/55, A61K47/64
Quick answer
US 9657288 (Connector compound peptide phage display) is held by BICYCLE THERAPEUTICS LIMITED. Status: granted. Granted May 23, 2017. Expires May 18, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BICYCLE THERAPEUTICS LIMITED
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K47/54, A61K47/55, A61K47/64
More from BICYCLE THERAPEUTICS LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12378288
Multimeric bicyclic peptide ligands
granted -
US 12377155
Bicyclic peptide ligands specific for PSMA
granted -
US 12350343
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 12049520
Bicyclic peptide ligands specific for CD137
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11970553
Heterotandem bicyclic peptide complex
granted
Frequently asked questions
What is US patent 9657288?
US 9657288 (Connector compound peptide phage display) is held by BICYCLE THERAPEUTICS LIMITED. Status: granted. Granted May 23, 2017. Expires May 18, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9657288?
BICYCLE THERAPEUTICS LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 9657288 expire?
Our index shows an expiration date of May 18, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.